参考文献/References:
[1] LV W,BOOZ G W,WANG Y,et al.Inflammation and renal fibrosis:recent developments on key signaling molecules as potential therapeutic targets[J].〖KG-\*8〗Eur J Pharmacol,2018,820:65-76.
[2] SUZUKI D,MIYAZAKI M,NAKA R,et al.In situ hybridization of interleukin 6 in diabetic nephropathy[J].Diabetes,1995,44(10):1233-1238.
[3] HUYNH P,CHAI Z.〖KG-\*8〗Transforming growth factor β (TGFβ) and related molecules in chronic kidney disease (CKD)[J].Clin Sci (Lond),2019,133(2):287-313.
[4] MOU X,ZHOU D Y,ZHOU D Y,et al.Serum TGF-β1 as a biomarker for type 2 diabetic nephropathy:a meta-analysis of randomized controlled trials[J].PLoS One,2016,11(2):e149513.
[5] SUN J,WANG Y,CUI W,et al.Role of epigenetic histone modifications in diabetic kidney disease involving renal fibrosis[J].J Diabetes Res,2017,2017:7242384.
[6] WANG X,LIU J,ZHEN J,et al.Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy[J].Kidney Int,2014,86(4):712-725.
[7] MORENO J A,GOMEZ-GUERRERO C,MAS S,et al.Targeting inflammation in diabetic nephropathy:a tale of hope[J].Expert Opin Investig Drugs,2018,27(11):917-930.
[8] PFFFLIN A,BRODBECK K,HEILIG C W,et al.Increased glucose uptake and metabolism in mesangial cells overexpressing glucose transporter 1 increases interleukin-6 and vascular endothelial growth factor production:role of AP-1 and HIF-1alpha[J].Cell Physiol Biochem,2006,18(4-5):199-210.
[9] NAVARRO J F,MILENA F J,MORA C,et al.Renal pro-inflammatory cytokine gene expression in diabetic nephropathy:effect of angiotensin-converting enzyme inhibition and pentoxifylline administration[J].Am J Nephrol,2006,26(6):562-570.
[10] ABDELRAHMAN A M,AL SULEIMANI Y,SHALABY A,et al.Effect of tocilizumab,an interleukin-6 inhibitor,on early stage streptozotocin-induced diabetic nephropathy in rats[J].Naunyn Schmiedebergs Arch Pharmacol,2019,392(8):1005-1013.
[11] SARAIVA M,VIEIRA P,O′GARRA A.Biology and therapeutic potential of interleukin-10[J].J Exp Med,2020,217(1):e20190418.
[12] KITCHING A R,KATERELOS M,MUDGE S J,et al.Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis[J].Clin Exp Immunol,2002,128(1):36-43.
[13] MU W,OUYANG X,AGARWAL A,et al.IL-10 suppresses chemokines,inflammation,and fibrosis in a model of chronic renal disease[J].J Am Soc Nephrol,2005,16(12):3651-3660.
[14] JIN Y,LIU R,XIE J,et al.Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model[J].Lab Invest,2013,93(7):801-811.
[15] WANG L,WANG H L,LIU T T,et al.TGF-beta as a master regulator of diabetic nephropathy[J].Int J Mol Sci,2021,22(15):7881.
[16] LAN H Y.Transforming growth factor-β/Smad signalling in diabetic nephropathy[J].Clin Exp Pharmacol Physiol,2012,39(8):731-738.
[17] WEI J,SHI Y,HOU Y,et al.Knockdown of thioredoxin-interacting protein ameliorates high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells[J].Cell Signal,2013,25(12):2788-2796.
[18] QI W,NIU J,QIN Q,et al.Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells[J].Cell Stress Chaperones,2014,19(1):105-114.
[19] LIU X X,ZHOU H J,CAI L,et al.NADPH oxidase-dependent formation of reactive oxygen species contributes to transforming growth factor β1-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells,and the role of astragalus intervention[J].〖KG-\*8〗Chin J Integr Med,2014,20(9)〖KG-\*8〗:667-674.
[20] SUN G,REDDY M A,YUAN H,et al.Epigenetic histone methylation modulates fibrotic gene expression[J].J Am Soc Nephrol,2010,21(12)〖KG-\*8〗:2069-2080.
[21] WEI Q,DONG Z.HDAC4 blocks autophagy to trigger podocyte injury:non-epigenetic action in diabetic nephropathy[J].Kidney Int,2014,86(4)〖KG-\*8〗:666-668.
[22] SHI W,HUANG Y,ZHAO X,et al.Histone deacetylase 4 mediates high glucose-induced podocyte apoptosis via upregulation of calcineurin[J].Biochem Biophys Res Commun,2020,533(4):1061-1068.
相似文献/References:
[1]袁慧娟 翁孝刚 窦敬芳 郭永年.芎嗪对实验性糖尿病大鼠肾脏的保护作用[J].新乡医学院学报,1999,16(04):331.
[2]乔立新,张兴国,熊芬霞,等.益气活血胶囊的制备及其治疗Ⅱ型糖尿病的疗效[J].新乡医学院学报,2001,18(06):404.
[3]翁孝刚. 赵誉洲,陈三敏,越志勇. 郭永年.川芎嗪、山茛菪碱、蝮蛇抗栓酶及卡托普利对糖尿病大鼠肾脏的保护作用[J].新乡医学院学报,2001,18(01):020.
[4]杨福燕,魏崇一,王凤业,等.阿魏酸钠对糖尿病肾病患者血浆内皮素的影响[J].新乡医学院学报,2003,20(03):199.
[5]杨福燕,魏崇一,王凤业,等.阿魏酸钠对糖尿病肾病患者血浆内皮素的影响[J].新乡医学院学报,2003,20(03):199.
[6]王晓青,李 竞,王鹏虎.氯沙坦联合苯那普利对早期糖尿病肾病患者血清TGF2β1 及MCP21的影响[J].新乡医学院学报,2006,23(05):517.
[7]游然,张同帅.奥扎格雷钠治疗糖尿病肾病疗效观察 TitleFilter('chTitle');[J].新乡医学院学报,2010,27(04):382.
[8]王佳贺,任开明,姜洪芳,等.肠致病性大肠杆菌毒力因子EspF对肿瘤坏死因子-α、白细胞介素-6 和白细胞介素-8的影响[J].新乡医学院学报,2011,28(03):265.
WANG Jia-he,REN Kai-ming,JIANG Hong-fang,et al.Effect of virulence factor EspF from enteropathic E.coli on tumor necrosis factor-α,interleukin-6[J].Journal of Xinxiang Medical University,2011,28(8):265.
[9]谭静.糖尿病肾病患者血清C 反应蛋白、肿瘤坏死因子-α 和血管内皮生长因子水平变化[J].新乡医学院学报,2012,29(09):678.
[10]张 慧,张 婷,宋 宇,等.薏苡仁对实验性腹腔粘连大鼠腹腔液炎性相关因子及粘连组织血管内皮生长因子、血管内皮标志物CD34表达的影响[J].新乡医学院学报,2014,31(10):792.[doi:10.7683/xxyxyxb.2014.10.006]